{
  "abstract": "Background: The current 8-week regimen of rifampicin and clarithromycin for Buruli ulcer (BU) is suboptimal. High-dose rifampicin could shorten treatment and improve outcomes. We evaluated whether a 4-week high-dose regimen could improve time to clearance of viable Mycobacterium ulcerans. Methodology: In this open-label, individually randomised trial conducted in Ghana, participants with PCR-confirmed BU were assigned (1:1) to either high-dose oral rifampicin (20mg/kg) with clarithromycin (15mg/kg) for 4 weeks (HR) or standard-dose rifampicin (10mg/kg) with clarithromycin (15mg/kg) for 8 weeks (SR). All wounds were dressed with DACC-coated dressings. The primary outcome was time to clearance of viable M. ulcerans assessed by 16S rRNA qPCR up to week 20. Findings: Between 26th November 2021 and 31st July 2024, 42 participants were randomised (HR:23, SR:19), which was short of the target (n = 112). The mean time to clearance was 4.9 weeks (SE 1.4) in the HR arm versus 7.0 weeks (SE 1.9) in the SR arm, with an adjusted mean difference of -0.5 weeks (95%CI -5.0 to 4.1, p = 0.835). No recurrences occurred in either arm. Paradoxical reactions were observed in 0/21 participants in the HR arm vs. 5/15 in the SR arm (adjusted OR 0.19, 95%CI 0.00-1.35, p = 0.102). Secondary infection rates were similar between groups. Conclusion: High‑dose rifampicin combination for 4 weeks was well tolerated in this population. A nominally lower proportion of paradoxical reactions was observed in the high-dose rifampicin arm compared with standard therapy. The trial did not find evidence of significantly shorter time to microbiological clearance or healing compared with standard therapy. Larger trials are needed to determine efficacy and safety. Trial Registration: Pan African Clinical Trials Repository, trial registration number: PACTR202011867644311 (https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=14534). Author summary: Buruli ulcer (BU) is a neglected tropical disease that causes destructive skin lesions and long-term disability, particularly in rural communities. The current standard treatment, eight weeks of rifampicin and clarithromycin, is effective but lengthy, which can reduce adherence and increase the burden on patients and health services. This study explored whether a high-dose rifampicin regimen could offer a safe, shorter, and more convenient alternative. In a randomized clinical trial conducted in Ghana, we compared a 4-week high-dose rifampicin regimen with the standard 8-week treatment. We assessed how quickly the bacteria causing BU were cleared from the wounds of affected individuals and monitored safety outcomes. The results showed that the shorter, high-dose regimen was not superior but was well tolerated and achieved similar bacterial clearance and healing times compared to standard treatment although we enrolled fewer participants than planned and the intervention and control groups were not evenly balanced. Notably, patients receiving the high-dose regimen experienced fewer paradoxical reactions, a common inflammatory complication during treatment. These findings suggest that high-dose rifampicin may offer a promising strategy to shorten BU treatment time. However, larger studies are needed to confirm its efficacy, safety and potential to shorten treatment duration while maintaining good outcomes.",
  "abstract_shown": true,
  "affiliations": [
    "Centre for Collaborative Research, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana",
    "School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana",
    "Department of Medical Statistics and the Clinical Trials Unit, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom",
    "Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana",
    "Centre for Social Policy Studies, University of Ghana, Accra, Ghana",
    "Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom",
    "Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom",
    "Hospital for Tropical Diseases, University College Hospital, London, United Kingdom"
  ],
  "article_type": "Research Article",
  "arxiv": null,
  "author_total": 20,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Abigail Agbanyo"
    },
    {
      "affs": [
        1
      ],
      "name": "Yaw Ampem Amoako"
    },
    {
      "affs": [
        2
      ],
      "name": "Charles Opondo"
    },
    {
      "affs": [
        3
      ],
      "name": "Michael Ntiamoah Oppong"
    },
    {
      "affs": [
        4
      ],
      "name": "Adwoa Asante-Poku"
    },
    {
      "affs": [
        5
      ],
      "name": "Jacob Novignon"
    },
    {
      "affs": [
        6
      ],
      "name": "Joseph Tuffour"
    },
    {
      "affs": [
        7
      ],
      "name": "Ishaque Saim Mintah"
    },
    {
      "name": "Ruth Dede Tuwor"
    },
    {
      "name": "Dzifa Kofi Ahiatrogah"
    },
    {
      "name": "Richard Adjei Akuffo"
    },
    {
      "name": "Miriam Gborglah"
    },
    {
      "name": "Iris Mosweu"
    },
    {
      "name": "Catherine Pitt"
    },
    {
      "name": "Elizabeth Allen"
    },
    {
      "name": "Stephen L. Walker"
    },
    {
      "name": "Dorothy Yeboah-Manu"
    },
    {
      "name": "Michael Marks"
    },
    {
      "name": "Richard Odame Phillips"
    },
    {
      "name": "SHARP Collaboration"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5pptfxvg4yjtn.bib",
  "cited_by": 0,
  "doi": "10.1371/journal.pntd.0014783",
  "fulltext_url": "https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0014783",
  "id": "5pptfxvg4yjtn",
  "issns": [
    "1935-2735"
  ],
  "landing_url": "https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0014783",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2713|Mycobacterium research and diagnosis"
    ],
    [
      "plos",
      "/Biology and life sciences/Biochemistry/Nucleic acids/RNA/Non-coding RNA/Ribosomal RNA"
    ],
    [
      "plos",
      "/Biology and life sciences/Biochemistry/Ribosomes/Ribosomal RNA"
    ],
    [
      "plos",
      "/Biology and life sciences/Cell biology/Cellular structures and organelles/Ribosomes/Ribosomal RNA"
    ],
    [
      "plos",
      "/Biology and life sciences/Microbiology/Microbial control/Antimicrobials/Antibiotics"
    ],
    [
      "plos",
      "/Biology and life sciences/Neuroscience/Cognitive science/Cognitive psychology/Perception/Sensory perception/Pruritus"
    ],
    [
      "plos",
      "/Biology and life sciences/Neuroscience/Sensory perception/Pruritus"
    ],
    [
      "plos",
      "/Biology and life sciences/Organisms/Bacteria/Actinobacteria/Mycobacterium ulcerans"
    ],
    [
      "plos",
      "/Biology and life sciences/Physiology/Physiological processes/Tissue repair/Wound healing"
    ],
    [
      "plos",
      "/Biology and life sciences/Psychology/Cognitive psychology/Perception/Sensory perception/Pruritus"
    ],
    [
      "plos",
      "/Medicine and health sciences/Clinical medicine/Signs and symptoms/Lesions"
    ],
    [
      "plos",
      "/Medicine and health sciences/Medical conditions/Infectious diseases/Bacterial diseases/Buruli ulcer"
    ],
    [
      "plos",
      "/Medicine and health sciences/Medical conditions/Tropical diseases/Neglected tropical diseases/Buruli ulcer"
    ],
    [
      "plos",
      "/Medicine and health sciences/Pharmacology/Drugs/Antimicrobials/Antibiotics"
    ],
    [
      "plos",
      "/Research and analysis methods/Research design/Clinical research design/Adverse events"
    ],
    [
      "plos",
      "/Social sciences/Psychology/Cognitive psychology/Perception/Sensory perception/Pruritus"
    ]
  ],
  "openalex": "W7214780792",
  "pdf_url": "https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0014783&type=printable",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-29",
  "publisher": "Public Library of Science",
  "ris": "https://research.draconitic.com/paper/5pptfxvg4yjtn.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:37Z",
      "native_id": "10.1371/journal.pntd.0014783",
      "source": "plos",
      "url": "https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0014783"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "plos:cell biology",
      "subfield": "cell-biology"
    },
    {
      "field": "biology",
      "origin": "plos:microbiology",
      "subfield": "microbiology"
    },
    {
      "field": "biology",
      "origin": "plos:neuroscience",
      "subfield": "neuroscience"
    }
  ],
  "title": "High-dose rifampicin and clarithromycin for 4 weeks versus standard-dose rifampicin and clarithromycin for 8 weeks to treat Buruli ulcer: An open-label, individually randomized, controlled trial in Ghana",
  "title_text": "High-dose rifampicin and clarithromycin for 4 weeks versus standard-dose rifampicin and clarithromycin for 8 weeks to treat Buruli ulcer: An open-label, individually randomized, controlled trial in Ghana",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:37Z",
  "url": "https://research.draconitic.com/paper/5pptfxvg4yjtn",
  "venue": "PLOS Neglected Tropical Diseases",
  "versions": []
}